We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $-0.21 | — | — | $0 | — | 예정 |
| FY2022 Q3 | 2022. 09. 30. | 시각 미정 | — | $-1.21 | — | — | $1.24B | 보고됨 |
| FY2022 Q2 | 2022. 06. 30. | 시각 미정 | — | — | — | — | $1.07B |
Consensus PT $6.83 · 6 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Citizens | — | 커버리지 개시 | — → Market Outperform | — | Citizens: Market Outperform |
| 2026. 04. 28. | D. Boral Capital | — | 의견 유지 | Buy → Buy | — | D. Boral Capital: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2022 Q1 | 2022. 03. 31. | 시각 미정 | — | — | — | — | $1.07B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 388,696 | $594.71M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 423,469 | $525.1M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Stored first · Google News · Yahoo Finance (English)
Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead - MSN
Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead MSN
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA) - The Globe and Mail
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA) The Globe and Mail
Biomea Fusion to Participate at Upcoming Investor Conferences - The Manila Times
Biomea Fusion to Participate at Upcoming Investor Conferences The Manila Times
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion to Participate at Upcoming Investor Conferences - GlobeNewswire
Biomea Fusion to Participate at Upcoming Investor Conferences GlobeNewswire
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 Moomoo